Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 3/20 | 0.79 |
| ▸ | USP2 | O75604 | 1/20 | 0.79 |
| ▸ | CDC25A | P30304 | 4/20 | 0.77 |
| ▸ | POLA1 | P09884 | 1/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.65 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.61 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19232373 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL4739364 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15372968 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL11371121 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL4739362 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL106015 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL24403430 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL10052613 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL12205280 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 | |
| SCHEMBL15289783 | 1.00 | VDR (0.79) | VDRUSP2CDC25APOLA1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785675-B2 | Compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-7618554-B2 | for in-plane switching (IPS) liquid crystal displays and low voltage-driven twist nematic (TN) liquid crystal displays and has a high dielectric anisotropy and a low rotational viscosity; perfluoroallyl difluorophenyl ethers | ADEKA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090103041-A1 | Novel compound and liquid crystal composition | ADEKA CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080149890-A1 | Liquid Crystal Composition | ADEKA CORPORATION (JP) | 2008-06-26 | — | — | US | disclosed |
| EP-1840185-A1 | LIQUID CRYSTAL COMPOSITION | Adeka Corporation (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090103041-A1 | Novel compound and liquid crystal composition | PYM1, H1-0, H1-2 | VDR 2126/4885USP2 3375/4885CDC25A 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.